Analyst Ratings For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Today, LADENBURG THALM/SH SH initiated coverage on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) with a Buy with a price target of $7.00.
There are 5 Buy Ratings, 3 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) is Buy with a consensus target price of $5.50 per share, a potential 77.42% upside.
Some recent analyst ratings include
- 8/16/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Buy rating and $7.00 price target
- 8/7/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by HC Wainwright
- 8/3/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer
- 8/2/2018-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by Cantor Fitzgerald with a $6.00 price target
- 10/13/2017-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Piper Jaffray Companies with a $2.00 price target
- 10/13/2017-AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) gets downgraded to Hold by Jefferies Financial Group
Recent Insider Trading Activity For AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has insider ownership of 25.50% and institutional ownership of 7.08%.
- On 8/7/2018 Mark G Edwards, Director, bought 5,300 with an average share price of $2.84 per share and the total transaction amounting to $15,052.00.
- On 8/7/2018 Vincent J. Angotti, CEO, bought 10,000 with an average share price of $2.90 per share and the total transaction amounting to $29,000.00.
- On 8/6/2018 Pamela P. Palmer, Insider, bought 37,000 with an average share price of $2.75 per share and the total transaction amounting to $101,750.00.
- On 8/6/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $2.75 per share and the total transaction amounting to $13,750.00.
- On 6/5/2018 Mark G Edwards, Director, bought 5,000 with an average share price of $3.35 per share and the total transaction amounting to $16,750.00.
- On 6/1/2018 Mark G Edwards, Director, bought 300 with an average share price of $3.30 per share and the total transaction amounting to $990.00.
- On 5/25/2018 Raffi Asadorian, CFO, bought 5,000 with an average share price of $3.18 per share and the total transaction amounting to $15,900.00.
About AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Recent Trading Activity for AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)
Shares of AcelRx Pharmaceuticals Inc closed the previous trading session at 3,13 +0,18 6,10 % with 3.15 shares trading hands.